REG - Futura Medical PLC - Notice of Results

Futura MedicalAnnouncement

16/03/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200316:nRSP1732Ga

RNS Number : 1732G  Futura Medical PLC  16 March 2020

 

16  March 2020

 

Notice of Results 2019

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal technology DermaSys® and currently focused on sexual
health and pain, will announce its audited results for the year ended 31
December 2019 on Wednesday, 1 April 2020.

 

James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief
Operating Officer, and Ken James, Executive Director and Head of R&D, will
host a webcast for analysts on the day of the results, which will be made
available within the investor centre section of the Company's website.

 

In light of growing concerns regarding COVID-19, the Company has decided to
cancel its scheduled Investor Seminar, to be held on 26 March 2020.

The Results webcast will now incorporate the Investor Seminar presentation
which includes an extensive internal evaluation of the clinical data from the
Phase 3 study ("FM57"), ongoing research and analysis of MED3000, as well as
an update on regulatory discussions and insight into the erectile dysfunction
market presented by Professor David Ralph, world leading expert in erectile
dysfunction and male infertility and member of the Futura European KOL
Advisory Panel.

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com)

Nominated Adviser and Sole Broker:

Liberum

Bidhi Bhoma/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NORDXLFFBXLBBBQ